Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease

The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective study in patients with Crohn’s disease analysing gut microbiota before start of adalimumab therapy (T0) and after six months of therapy (T1). Among the 20 included patients, the phylum Proteobacteria fell from 15.7 ± 3.5% at T0 to 10.3 ± 3.4% at T1 (p = 0.038). Furthermore, the trend in relation to therapeutic success was analysed. Regarding bacterial phyla, Proteobacteria decreased in patients in whom therapeutic success was obtained, passing from a value of 15.8% (± 4.6%) to 6.8 ± 3.1% (p = 0.049), while in non-responder patients, percentages did not change (T0 = 15.6 ± 5.7%, T1 = 16.8 ± 7.6%, p = 0.890). Regarding the Lachnospiraceae family, in patients with normalization of C reactive protein six 6 months of adalimumab therapy, it increased from 16.6 ± 3.1% at T0 to 23.9 ± 2.6% at T1 (p = 0.049). In conclusion, in patients who respond to Adalimumab therapy by decreasing inflammation, there is a trend of intestinal eubiosis being restored.

[1]  Lajia Zha,et al.  Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome , 2019, Pathogens.

[2]  S. Fagoonee,et al.  Physiopathology of intestinal barrier and the role of zonulin , 2019, Minerva Biotecnologica.

[3]  G. Actis,et al.  Inflammation in gastrointestinal disorders: prevalent socioeconomic factors , 2019, Clinical and experimental gastroenterology.

[4]  Jessica K. Lang,et al.  The Crohn’s disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response , 2019, eLife.

[5]  A. Petersen,et al.  Disease-Specific Enteric Microbiome Dysbiosis in Inflammatory Bowel Disease , 2018, Front. Med..

[6]  G. Actis,et al.  Pathogenesis of Inflammatory Bowel Disease: Basic Science in the Light of Real-World Epidemiology , 2018, Gastrointestinal Disorders.

[7]  D. Raoult,et al.  From Culturomics to Clinical Microbiology and Forward , 2018, Emerging infectious diseases.

[8]  S. Lal,et al.  The Human Gut Microbiome – A Potential Controller of Wellness and Disease , 2018, Front. Microbiol..

[9]  G. Actis,et al.  Inflammation: a highly conserved, Janus-like phenomenon—a gastroenterologist’ perspective , 2018, Journal of Molecular Medicine.

[10]  P. Schloss,et al.  Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn’s Disease Patients , 2018, mBio.

[11]  Guangjun Yu,et al.  Characteristics of Faecal Microbiota in Paediatric Crohn’s Disease and Their Dynamic Changes During Infliximab Therapy , 2018, Journal of Crohn's & colitis.

[12]  John T. Chang,et al.  Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease , 2018, Clinical and Translational Gastroenterology.

[13]  A. Eggermont,et al.  Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[15]  Ashwin N Ananthakrishnan,et al.  Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. , 2017, Cell host & microbe.

[16]  N. Kamada,et al.  Host-microbial Cross-talk in Inflammatory Bowel Disease , 2017, Immune network.

[17]  A. Gálvez,et al.  The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: a state of the science review , 2017, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[18]  H. Tilg,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.

[19]  Eric Z. Chen,et al.  Inflammation, Antibiotics, and Diet as Environmental Stressors of the Gut Microbiome in Pediatric Crohn's Disease. , 2017, Cell host & microbe.

[20]  S. Turroni,et al.  Gut Bifidobacteria Populations in Human Health and Aging , 2016, Front. Microbiol..

[21]  B. Simionati,et al.  A Multi-Omics Approach to Evaluate the Quality of Milk Whey Used in Ricotta Cheese Production , 2016, Front. Microbiol..

[22]  L. Öhman,et al.  Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition. , 2016, Journal of Crohn's & colitis.

[23]  Yava L Jones-Hall,et al.  The Intersection of TNF, IBD and the Microbiome , 2016, Gut microbes.

[24]  H. Flint,et al.  Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. , 2015, FEMS microbiology letters.

[25]  J. Garcia-Gil,et al.  Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease. , 2015, Journal of Crohn's & colitis.

[26]  Jagdeep Nanchahal,et al.  Anti-TNF therapy: past, present and future. , 2015, International immunology.

[27]  E. Louis,et al.  Alterations in the Intestinal Microbiome (Dysbiosis) as a Predictor of Relapse After Infliximab Withdrawal in Crohn's Disease , 2014, Inflammatory bowel diseases.

[28]  W. Reinisch,et al.  Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? , 2013, Best practice & research. Clinical gastroenterology.

[29]  Eric J. Alm,et al.  Non-Invasive Mapping of the Gastrointestinal Microbiota Identifies Children with Inflammatory Bowel Disease , 2012, PloS one.

[30]  A. Ford,et al.  Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience. , 2011, Journal of Crohn's & colitis.

[31]  P. Vandamme,et al.  Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives , 2011, Gut.

[32]  K. Voelkerding,et al.  Next-generation sequencing: from basic research to diagnostics. , 2009, Clinical chemistry.

[33]  M. Sakamoto,et al.  Bacteroides ovatus as the Predominant Commensal Intestinal Microbe Causing a Systemic Antibody Response in Inflammatory Bowel Disease , 2002, Clinical and Vaccine Immunology.